FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
10/10/2025
Voltar para busca
Dado oficial do USPTO
EFESA
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: MistaEscritório: US
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
32
Atualização mais recente
03/04/2026
Classificação
Registrada
Tipo de marca
Mista
Classes Nice
5
Data de depósito
22/12/2023
Data de registro
04/03/2025
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
04/03/2025
Última transação
03/04/2026
Escritório responsável
United States Patent and Trademark Office
Código da situação
700
Cadastro oficial
Principal Register
Código do desenho
5
Tipo de titular
03
Localização do titular
KR
Examinador
FLETCHER, TRACY L
Unidade examinadora
M60
Localização atual
FILE REPOSITORY (FRANCONIA)
Titulares e representantes
Titulares
Genexine, Inc.
Representantes
Patricia A Wilczynski Brozek POKALSKY WILCZYNSKI BROZEK LLP
Classificação técnica
Classes Nice
Classe 5
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 5
Pharmaceutical preparations for the treatment of diseases of the endocrine system; pharmaceutical agents affecting metabolism; cardiovascular treatment preparations; cardiovascular pharmaceutical preparations; pharmaceutical preparations for the treatment of kidney disorders; pharmaceutical preparations for the treatment of kidney diseases; pharmaceutical preparations for the treatment of diseases of the metabolic system; pharmaceutical preparations for the treatment of cardiovascular disease; medicines for the treatment of cardiovascular and cerebrovascular diseases; pills for dizziness symptoms treatment being pharmaceutical preparations for the treatment of dizziness; biological preparations for medical purposes being biological preparations for the treatment of anemiakidney disease and kidney disorders; cardiovascular agents for medical purposes; drugs for medical purposes being pharmaceutical preparations for the treatment of anemiakidney disease and kidney disorders; synthetic peptides for pharmaceutical purposes being synthetic peptides for the treatment of anemiakidney disease and kidney disorders; pharmaceuticals being pharmaceutical preparations for the treatment of anemiakidney disease and kidney disorders; medicines for human purposes being pharmaceutical preparations for the treatment of anemiakidney disease and kidney disorders; anemia treatment medicines that stimulate red blood cell production being pharmaceutical preparations for the treatment of anemia; medicines to stimulate red blood cell production being pharmaceutical preparations for the treatment of anemia; pharmaceutical preparations for treatment of chronic kidney disease and anemia; biological preparations for treatment of anemia; biological preparations to stimulate red blood cell production for veterinary and medical purposes being biological preparations for the treatment of anemia; synthetic peptides for pharmaceutical and anemia treatment purposes being synthetic peptides for the treatment of anemia; synthetic peptides for pharmaceutical and kidney disease treatment purposes being synthetic peptides for the treatment of kidney disease
Publicações
Histórico de despachos e eventos da marca no USPTO.
32 publicações encontradas
FICS
FINAL DISPOSITION NOTICE SENT TO IB
19/09/2025
FIMP
FINAL DISPOSITION PROCESSED
19/09/2025
OPNX
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
29/08/2025
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
13/08/2025
OPNR
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
13/08/2025
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
05/06/2025
R.PR
REGISTERED-PRINCIPAL REGISTER
04/03/2025
NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
04/03/2025
NREP
NEW REPRESENTATIVE AT IB RECEIVED
07/02/2025
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
14/01/2025
PUBO
PUBLISHED FOR OPPOSITION
14/01/2025
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
08/01/2025
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
19/12/2024
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
19/12/2024
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
19/12/2024
ERFR
TEAS REQUEST FOR RECONSIDERATION RECEIVED
19/12/2024
GNFN
NOTIFICATION OF FINAL REFUSAL EMAILED
22/11/2024
GNFR
FINAL REFUSAL E-MAILED
22/11/2024
CNFR
FINAL REFUSAL WRITTEN
22/11/2024
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
12/11/2024
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
12/11/2024
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
12/11/2024
RFNT
REFUSAL PROCESSED BY IB
25/08/2024
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
08/08/2024
RFRR
REFUSAL PROCESSED BY MPU
08/08/2024
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
24/07/2024
CNRT
NON-FINAL ACTION WRITTEN
23/07/2024
DOCK
ASSIGNED TO EXAMINER
23/07/2024
MAFR
APPLICATION FILING RECEIPT MAILED
24/04/2024
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
22/03/2024
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
14/03/2024
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace EFESA ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.